1-4 of 4
John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020
Journal Articles

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Johannes Bloehdorn, MD, Andrejs Braun, PhD, Billy Michael Chelliah Jebaraj, PhD, Amaro Taylor-Weiner, PhD, Sandra Robrecht, PhD, Julia Krzykalla, PhD, Karlheinz Holzmann, PhD, Harvey Johnston, PhD, Tetyana Klymenko, PhD, Barbara Eichhorst, MD, Ru-Fang Yeh, PhD, Martin Weisser, MD, Jennifer Edelmann, MDPhD, Kirsten Fischer, MD, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Dan A. Landau, MD PhD, Donna S. Neuberg, ScD, Mark S Cragg, PhD, Axel Benner, Michael Hallek, MD, Catherine J. Wu, MD, Hartmut Döhner, Stephan Stilgenbauer, MD, Daniel Mertens, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-141552
Published: 2020
Journal Articles

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

John F. Seymour, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Matthew S. Davids, MD, Anthony Mato, MD, Jeff P Sharman, MD, Aimee Cyr, Cynthia Bartkus, German Pena, MD, Michelle Boyer, Simon Sharmokh, MPH, PharmD, Tanya S Rosenberg, MD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-134938
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020